GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Current Ratio

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Current Ratio : 3.30 (As of Mar. 2018)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Anthera Pharmaceuticals's current ratio for the quarter that ended in Mar. 2018 was 3.30.

Anthera Pharmaceuticals has a current ratio of 3.30. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Anthera Pharmaceuticals's Current Ratio or its related term are showing as below:

ANTH's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.71
* Ranked among companies with meaningful Current Ratio only.

Anthera Pharmaceuticals Current Ratio Historical Data

The historical data trend for Anthera Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals Current Ratio Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 0.53 5.65 2.14 0.68

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 3.28 1.97 0.68 3.30

Competitive Comparison of Anthera Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Anthera Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Current Ratio falls into.



Anthera Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Anthera Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Current Ratio (A: Dec. 2017 )=Total Current Assets (A: Dec. 2017 )/Total Current Liabilities (A: Dec. 2017 )
=3.191/4.711
=0.68

Anthera Pharmaceuticals's Current Ratio for the quarter that ended in Mar. 2018 is calculated as

Current Ratio (Q: Mar. 2018 )=Total Current Assets (Q: Mar. 2018 )/Total Current Liabilities (Q: Mar. 2018 )
=8.739/2.646
=3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anthera Pharmaceuticals  (OTCPK:ANTH) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Anthera Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines